{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:26:22Z","timestamp":1783121182112,"version":"3.54.6"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.ejmech.2016.05.039","type":"journal-article","created":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T23:54:25Z","timestamp":1464134065000},"page":"671-698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Contemporary developments in the discovery of selective factor Xa inhibitors: A review"],"prefix":"10.1016","volume":"121","author":[{"given":"Nirav R.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dushyant V.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant R.","family":"Murumkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mange Ram","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2016.05.039_bib1","unstructured":"http:\/\/www.who.int\/mediacentre\/factsheets\/fs317\/en\/ (accessed on 21.04.16)."},{"key":"10.1016\/j.ejmech.2016.05.039_bib2","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1161\/CIRCULATIONAHA.110.936773","article-title":"Pathophysiology of bleeding and clotting in the cardiac surgery patient: from vascular endothelium to circulatory assist device surface","volume":"122","author":"Achneck","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2016.05.039_bib3","unstructured":"http:\/\/www.cdc.gov\/ncbddd\/dvt\/data.html (accessed on 21.04.16)."},{"key":"10.1016\/j.ejmech.2016.05.039_bib4","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1160\/TH07-03-0212","article-title":"Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality","volume":"98","author":"Cohen","year":"2007","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejmech.2016.05.039_bib5","doi-asserted-by":"crossref","first-page":"669S","DOI":"10.1378\/chest.11-2307","article-title":"Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Alonso-Coello","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ejmech.2016.05.039_bib6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nrcardio.2014.222","article-title":"Antithrombotic therapy in 2014: making headway in anticoagulant and antiplatelet therapy","volume":"12","author":"Fareed","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejmech.2016.05.039_bib7","doi-asserted-by":"crossref","first-page":"419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ejmech.2016.05.039_bib8","series-title":"Seminars in Thrombosis and Hemostasis","first-page":"885","article-title":"Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective","author":"Lijfering","year":"2011"},{"key":"10.1016\/j.ejmech.2016.05.039_bib9","doi-asserted-by":"crossref","first-page":"120S","DOI":"10.1378\/chest.11-2294","article-title":"New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Weitz","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ejmech.2016.05.039_bib10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejmech.2012.09.016","article-title":"Synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing a cleavable moiety with anti-platelet activity","volume":"57","author":"Yang","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib11","doi-asserted-by":"crossref","first-page":"531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ejmech.2016.05.039_bib12","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrcardio.2011.91","article-title":"Arterial thrombus formation in cardiovascular disease","volume":"8","author":"Lippi","year":"2011","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejmech.2016.05.039_bib13","doi-asserted-by":"crossref","first-page":"I-3","DOI":"10.1161\/01.CIR.0000140904.52752.0c","article-title":"Initial treatment of venous thromboembolism","volume":"110","author":"McRae","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2016.05.039_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2344\/0003-3006-60.2.72","article-title":"Antithrombotic drugs: pharmacology and implications for dental practice","volume":"60","author":"Becker","year":"2013","journal-title":"Anesth. Prog."},{"key":"10.1016\/j.ejmech.2016.05.039_bib15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(15)60243-4","article-title":"Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments","volume":"386","author":"Mega","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2016.05.039_bib16","first-page":"396","article-title":"Anticoagulant therapy for ischemic stroke: a review of literature","volume":"17","author":"Shahpouri","year":"2012","journal-title":"J.\u00a0Res. Med. Sci."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.ejmech.2016.05.039_bib17","first-page":"S72","article-title":"Therapeutic level of oral anticoagulation with warfarin in patients with mechanical prosthetic heart valves: review of literature and recommendations based on international normalized ratio","volume":"70","author":"Stein","year":"1994","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.ejmech.2016.05.039_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1161\/CIRCULATIONAHA.111.019786","article-title":"A\u00a0patient\u2019s guide to taking dabigatran etexilate","volume":"124","author":"Spinler","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2016.05.039_bib19","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1056\/NEJMoa0806450","article-title":"Outbreak of adverse reactions associated with contaminated heparin","volume":"359","author":"Blossom","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2016.05.039_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0029-1214144","article-title":"Milestones and perspectives in coagulation and hemostasis","volume":"35","author":"Lippi","year":"2009","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.ejmech.2016.05.039_bib21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4103\/0019-5049.144643","article-title":"Overview of the coagulation system","volume":"58","author":"Palta","year":"2014","journal-title":"Indian J. Anaesth."},{"key":"10.1016\/j.ejmech.2016.05.039_bib22","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/BF03022247","article-title":"From normal to pathological hemostasis","volume":"53","author":"Lasne","year":"2006","journal-title":"Can. J. Anaesth."},{"key":"10.1016\/j.ejmech.2016.05.039_bib23","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1055\/s-0029-1145257","article-title":"Pathogenesis of venous thromboembolism: when the cup runneth over","volume":"34","author":"Lippi","year":"2008","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.ejmech.2016.05.039_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00431-011-1532-4","article-title":"Clinical practice: the bleeding child. Part I: primary hemostatic disorders","volume":"171","author":"van Ommen","year":"2012","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ejmech.2016.05.039_bib25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/0192623310389474","article-title":"Current understanding of hemostasis","volume":"39","author":"Gale","year":"2011","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ejmech.2016.05.039_bib26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1538-7836.2007.02473.x","article-title":"Factor Xa or thrombin: is factor Xa a better target?","volume":"5","author":"Ansell","year":"2007","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ejmech.2016.05.039_bib27","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1126\/science.145.3638.1310","article-title":"Waterfall sequence for intrinsic blood clotting","volume":"145","author":"Davie","year":"1964","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2016.05.039_bib28","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/med.20183","article-title":"Developments in factor Xa inhibitors for the treatment of thromboembolic disorders","volume":"31","author":"Lee","year":"2011","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2016.05.039_bib29","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/ATVBAHA.107.141911","article-title":"Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis","volume":"27","author":"Mackman","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2016.05.039_bib30","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1021\/jm100146h","article-title":"Factor Xa inhibitors: next-generation antithrombotic agents","volume":"53","author":"Pinto","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib31","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/202498a0","article-title":"An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier","volume":"202","author":"Macfarlane","year":"1964","journal-title":"Nature"},{"issue":"1977","key":"10.1016\/j.ejmech.2016.05.039_bib32","first-page":"376","article-title":"The chemistry of blood coagulation: a summary by Paul Morawitz","volume":"37","author":"Beck","year":"1905","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejmech.2016.05.039_bib33","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1440-1797.2009.01128.x","article-title":"Review article: coagulation cascade and therapeutics update: relevance to nephrology. Part 1: overview of coagulation, thrombophilias and history of anticoagulants","volume":"14","author":"Adams","year":"2009","journal-title":"Nephrology (Carlton Vic.)"},{"key":"10.1016\/j.ejmech.2016.05.039_bib34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/1043454206298693","article-title":"Theories of blood coagulation","volume":"24","author":"Riddel","year":"2007","journal-title":"J.\u00a0Pediatr. Oncol. Nurs."},{"key":"10.1016\/j.ejmech.2016.05.039_bib35","doi-asserted-by":"crossref","first-page":"10363","DOI":"10.1021\/bi00107a001","article-title":"The coagulation cascade: initiation, maintenance, and regulation","volume":"30","author":"Davie","year":"1991","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2016.05.039_bib36","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/eurheartj\/ehl492","article-title":"Anticoagulants in heart disease: current status and perspectives","volume":"28","author":"De Caterina","year":"2007","journal-title":"Eur. Heart. J."},{"key":"10.1016\/j.ejmech.2016.05.039_bib37","first-page":"391","article-title":"Rethinking the coagulation cascade","volume":"4","author":"Hoffman","year":"2005","journal-title":"Curr. Hematol. Rep."},{"key":"10.1016\/j.ejmech.2016.05.039_bib38","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1160\/TH12-10-0772","article-title":"General mechanisms of coagulation and targets of anticoagulants (Section I). Position paper of the ESC working group on thrombosis \u2013 task force on anticoagulants in heart disease","volume":"109","author":"De Caterina","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejmech.2016.05.039_bib39","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1006\/jmbi.1993.1441","article-title":"Structure of human des (1-45) factor Xa at 2\u00b7 2 \u00c5 resolution","volume":"232","author":"Padmanabhan","year":"1993","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2016.05.039_bib40","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1021\/jm050101d","article-title":"Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-arboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor","volume":"48","author":"Roehrig","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2174\/1568026013395461","article-title":"The use of 3D structural data in the design of specific factor Xa inhibitors","volume":"1","author":"Maignan","year":"2001","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib42","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/0006-291X(68)90326-4","article-title":"On the active site of proteases. III. Mapping the active site of papain; specific peptide inhibitors of papain","volume":"32","author":"Schechter","year":"1968","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2016.05.039_bib43","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0022-2836(75)80005-2","article-title":"The refined crystal structure of bovine \u03b2-trypsin at 1 8 \u00c5 resolution: II. Crystallographic refinement, calcium binding site, benzamidine binding site and active site at pH 7 0","volume":"98","author":"Bode","year":"1975","journal-title":"J.\u00a0Mol. Bio."},{"key":"10.1016\/j.ejmech.2016.05.039_bib44","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/pro.5560010402","article-title":"The refined 1.9-\u00c5 X-ray crystal structure of d-Phe-Pro-Arg chloromethylketone-inhibited human \u03b1-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships","volume":"1","author":"Bode","year":"1992","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2016.05.039_bib45","doi-asserted-by":"crossref","first-page":"29988","DOI":"10.1074\/jbc.271.47.29988","article-title":"X-ray structure of active site-inhibited clotting factor Xa implications for drug design and substrate recognition","volume":"271","author":"Brandstetter","year":"1996","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib46","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1006\/jmbi.2001.5062","article-title":"Factorising ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition\u2020","volume":"313","author":"Dullweber","year":"2001","journal-title":"J.\u00a0Mol. Bio."},{"key":"10.1016\/j.ejmech.2016.05.039_bib47","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0223-5234(96)88248-1","article-title":"Molecular model of an interaction between factor Xa and DX-9065a, a novel factor Xa inhibitor: contribution of the acetimidoylpyrrolidine moiety of the inhibitor to potency and selectivity for serine proteases","volume":"30","author":"Katakura","year":"1995","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib48","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1021\/ci200185q","article-title":"Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches","volume":"51","author":"Bhunia","year":"2011","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2016.05.039_bib49","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1002\/anie.201004575","article-title":"Oral, direct thrombin and factor Xa inhibitors: the replacement for warfarin, leeches, and pig intestines?","volume":"50","author":"Straub","year":"2011","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2016.05.039_bib50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0014-5793(95)01190-P","article-title":"Crystal structures of factor Xa specific inhibitors in complex with trypsin: structural grounds for inhibition of factor Xa and selectivity against thrombin","volume":"375","author":"Stubbs","year":"1995","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib51","doi-asserted-by":"crossref","first-page":"8977","DOI":"10.1016\/S0021-9258(19)84477-0","article-title":"The prothrombinase-catalyzed activation of prothrombin proceeds through the intermediate meizothrombin in an ordered, sequential reaction","volume":"261","author":"Krishnaswamy","year":"1986","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib52","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/2040622312438934","article-title":"Novel anticoagulants in atrial fibrillation stroke prevention","volume":"3","author":"Norgard","year":"2012","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.ejmech.2016.05.039_bib53","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00018-002-8415-9","article-title":"Visions & reflections factor Xa - a promising target for drug development","volume":"59","author":"Kaiser","year":"2002","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2016.05.039_bib54","first-page":"272","article-title":"Factor Xa inhibitors: today and beyond","volume":"4","author":"Walenga","year":"2003","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.ejmech.2016.05.039_bib55","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1538-7933.2004.00649.x","article-title":"Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis","volume":"2","author":"Ieko","year":"2004","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ejmech.2016.05.039_bib56","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2174\/1389450116666150518095533","article-title":"Advances in inhibitors of FXa","volume":"16","author":"Liwei","year":"2015","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2016.05.039_bib57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/01.ATV.0000046238.23903.FC","article-title":"The dynamics of thrombin formation, Arterioscler","volume":"23","author":"Mann","year":"2003","journal-title":"Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2016.05.039_bib58","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1055\/s-0038-1665413","article-title":"Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants","volume":"78","author":"Morishima","year":"1997","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejmech.2016.05.039_bib59","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40262-013-0034-0","article-title":"Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment","volume":"52","author":"Graff","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2016.05.039_bib60","first-page":"125","article-title":"Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban","volume":"33","author":"Ordovas Baines","year":"2009","journal-title":"Farm. Hosp. organo Of. expr. Cient. Soc. Espanola Farm. Hosp."},{"key":"10.1016\/j.ejmech.2016.05.039_bib61","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1160\/TH09-09-0659","article-title":"Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development","volume":"103","author":"Ufer","year":"2010","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejmech.2016.05.039_bib62","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1538-7836.2009.03503.x","article-title":"Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits","volume":"7","author":"Wong","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejmech.2016.05.039_bib63","series-title":"Rivaroxaban for Stroke Prevention in Atrial Fibrillation: a Critical Review of the ROCKET AF Trial","author":"Paikin","year":"2012"},{"key":"10.1016\/j.ejmech.2016.05.039_bib64","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrd3185","article-title":"The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"10","author":"Perzborn","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2016.05.039_bib65","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","article-title":"The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement1","volume":"5","author":"Lassen","year":"2007","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ejmech.2016.05.039_bib66","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1160\/TH14-06-0547","article-title":"Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis","volume":"113","author":"Parasrampuria","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejmech.2016.05.039_bib67","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2217\/fca.13.98","article-title":"Betrixaban (PRT054021): pharmacology, dose selection and clinical studies","volume":"10","author":"Chan","year":"2014","journal-title":"Future Cardiol."},{"key":"10.1016\/j.ejmech.2016.05.039_bib68","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1016\/j.bmcl.2006.02.069","volume":"16","author":"Pinto","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib69","first-page":"343","article-title":"Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism","volume":"11","author":"Chan","year":"2015","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ejmech.2016.05.039_bib70","doi-asserted-by":"crossref","first-page":"e95354","DOI":"10.1371\/journal.pone.0095354","article-title":"Bleeding risk and mortality of edoxaban: a pooled meta-analysis of randomized controlled trials","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2016.05.039_bib71","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2016.05.039_bib72","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2016.05.039_bib73","unstructured":"http:\/\/www.rcsb.org\/pdb\/results\/results.do?qrid=69FC3F8F&tabtoshow=Current (accessed on 13.04.16)."},{"key":"10.1016\/j.ejmech.2016.05.039_bib74","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1016\/j.bmcl.2010.06.126","article-title":"Discovery of a factor Xa inhibitor (3R,4R)-1-(2,2-difluoro-ethyl)-pyrrolidine-3,4-dicarboxylic acid 3-[(5-chloro-pyridin-2-yl)-amide] 4-[[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide] as a clinical candidate","volume":"20","author":"Anselm","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib75","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.bmcl.2009.11.077","article-title":"Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs","volume":"20","author":"Kleanthous","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib76","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1021\/jm4005835","article-title":"5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor","volume":"56","author":"Meneyrol","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib77","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1515\/BC.2002.130","article-title":"(R)-3-Amidinophenylalanine-derived inhibitors of factor Xa with a novel active-site binding mode","volume":"383","author":"Mueller","year":"2002","journal-title":"Biol. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib78","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/anie.201107091","article-title":"Fragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexes","volume":"51","author":"Nazare","year":"2012","journal-title":"Angew. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib79","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1021\/jm030212h","article-title":"Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2\u2019-(aminosulfonyl)[1,1\u2019-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1)","volume":"46","author":"Pruitt","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib80","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.bmcl.2010.01.011","article-title":"Phenyltriazolinones as potent factor Xa inhibitors","volume":"20","author":"Quan","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib81","first-page":"213","article-title":"Molecular recognition at the active site of factor Xa: cation-pi interactions, stacking on planar peptide surfaces, and replacement of structural water","volume":"18","author":"Salonen","year":"2012","journal-title":"Chem. Weinheim Bergstrasse Ger."},{"key":"10.1016\/j.ejmech.2016.05.039_bib82","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1016\/j.bmcl.2011.06.098","article-title":"Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors","volume":"21","author":"Shi","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib83","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.bmcl.2011.01.129","article-title":"The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs","volume":"21","author":"Watson","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib84","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.1016\/j.bmc.2009.10.024","article-title":"Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part II: exploration of 6-6 fused rings as alternative S1 moieties","volume":"17","author":"Yoshikawa","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib85","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.bmcl.2011.01.132","article-title":"Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors","volume":"21","author":"Yoshikawa","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib86","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.bmcl.2011.01.131","article-title":"Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs","volume":"21","author":"Young","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib87","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/jm020384z","article-title":"Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand","volume":"46","author":"Choi-Sledeski","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib88","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1002\/anie.200806219","article-title":"Evidence for C-Cl\/C-Br...pi interactions as an important contribution to protein-ligand binding affinity","volume":"48","author":"Matter","year":"2009","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2016.05.039_bib89","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.bmcl.2003.11.079","article-title":"Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs","volume":"14","author":"Zhang","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib90","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1016\/j.bmcl.2007.06.051","article-title":"Anthranilamide inhibitors of factor Xa","volume":"17","author":"Mendel","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib91","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.bmc.2011.01.035","article-title":"2-aminomethylphenylamine as a novel scaffold for factor Xa inhibitor","volume":"19","author":"Mochizuki","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib92","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1016\/j.bmcl.2007.05.068","article-title":"Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors","volume":"17","author":"Nagata","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib93","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/0929867013373822","article-title":"Perspectives on factor Xa inhibition","volume":"8","author":"Rai","year":"2001","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib94","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ejmech.2015.04.025","article-title":"Design, synthesis and structure-activity relationship of oxazolidinone derivatives containing novel S4 ligand as FXa inhibitors","volume":"96","author":"Zhao","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib95","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1517\/13543770903270532","article-title":"Novel factor Xa inhibitors: a patent review","volume":"19","author":"de Candia","year":"2009","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2016.05.039_bib96","series-title":"In Annual Reports in Medicinal Chemistry","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0065-7743(08)60571-0","article-title":"Anticoagulants: thrombin and factor Xa inhibitors","author":"Fevig","year":"1999"},{"key":"10.1016\/j.ejmech.2016.05.039_bib97","first-page":"1509","article-title":"Factor Xa inhibitors: a review of the recent patent literature","volume":"3","author":"Ries","year":"2000","journal-title":"IDrugs"},{"key":"10.1016\/j.ejmech.2016.05.039_bib98","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/jm980072p","article-title":"N-Phenylamidines as selective inhibitors of human neuronal nitric oxide synthase:\u2009 structure\u2212activity studies and demonstration of in\u00a0vivo activity","volume":"41","author":"Collins","year":"1998","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib99","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1021\/jm980227t","article-title":"Design of benzamidine-type inhibitors of factor Xa","volume":"41","author":"Gabriel","year":"1998","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib100","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1055\/s-0037-1614941","article-title":"Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa","volume":"79","author":"Taniuchi","year":"1998","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejmech.2016.05.039_bib101","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/cmdc.201200224","article-title":"\u03b2-D-Glucosyl conjugates of highly potent inhibitors of blood coagulation factor Xa bearing 2-chorothiophene as a P1 potif","volume":"7","author":"Lopopolo","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2016.05.039_bib102","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1747-0285.2007.00539.x","article-title":"The discovery of (2R,4R)-N-(4-chlorophenyl)-N- (2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor","volume":"70","author":"Kohrt","year":"2007","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2016.05.039_bib103","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.bmcl.2009.02.111","article-title":"Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenz amide, a highly potent, selective, and orally efficacious factor Xa inhibitor","volume":"19","author":"Zhang","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib104","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bmcl.2007.11.019","article-title":"Structure and property based design of factor Xa inhibitors: biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs","volume":"18","author":"Young","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bmcl.2007.11.023","article-title":"Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs","volume":"18","author":"Young","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib106","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1021\/jm049884d","article-title":"Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 binding element","volume":"47","author":"Haginoya","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib107","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.bmc.2007.11.073","article-title":"Discovery of sulfonylalkylamides: a new class of orally active factor Xa inhibitors","volume":"16","author":"Imaeda","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib108","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.bmc.2008.12.037","article-title":"Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: a novel, potent and orally active direct inhibitor of factor Xa","volume":"17","author":"Nagata","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib109","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1021\/jm0497949","article-title":"Discovery of 1-(3\u2018-Aminobenzisoxazol-5\u2018-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2\u2018-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (Razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor","volume":"48","author":"Quan","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib110","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1021\/jm020578e","article-title":"Structure-based design of novel guanidine\/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants","volume":"46","author":"Lam","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib111","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1016\/j.bmcl.2006.08.027","article-title":"Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties","volume":"16","author":"Pinto","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib112","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.bmcl.2006.11.071","article-title":"Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues","volume":"17","author":"Qiao","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib113","series-title":"Google Patents","article-title":"Aminoheterocyclic compounds with antithrombotic\/anticoagulant effect","author":"Faull","year":"2000"},{"key":"10.1016\/j.ejmech.2016.05.039_bib114","doi-asserted-by":"crossref","first-page":"5176","DOI":"10.1016\/j.bmcl.2006.07.002","article-title":"Preparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective, and efficacious inhibitors of coagulation factor Xa","volume":"16","author":"Li","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib115","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0960-894X(98)00471-5","article-title":"The de novo design and synthesis of cyclic urea inhibitors of factor Xa: initial sar studies","volume":"8","author":"Galemmo","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib116","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1021\/jm070245n","volume":"50","author":"Pinto","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib117","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1747-0285.2007.00520.x","article-title":"Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitors","volume":"69","author":"Van Huis","year":"2007","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2016.05.039_bib118","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1016\/j.bmcl.2008.03.092","article-title":"Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties","volume":"18","author":"Corte","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib119","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1021\/jm070125f","article-title":"Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors 1","volume":"50","author":"Ye","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib120","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1248\/cpb.52.459","article-title":"Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors III. Effect of ring opening of piperazinone moiety on inhibition","volume":"52","author":"Nishida","year":"2004","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2016.05.039_bib121","doi-asserted-by":"crossref","first-page":"7770","DOI":"10.1021\/jm501045e","article-title":"Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor","volume":"57","author":"Xue","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib122","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.bmc.2005.09.056","article-title":"Design, synthesis, and biological activity of novel factor Xa inhibitors: improving metabolic stability by S1 and S4 ligand modification","volume":"14","author":"Komoriya","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib123","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1016\/j.bmcl.2006.04.044","article-title":"Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa","volume":"16","author":"Fevig","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib124","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bmcl.2006.01.010","article-title":"Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors","volume":"16","author":"Quan","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib125","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.bmcl.2003.11.079","article-title":"Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs","volume":"14","author":"Zhang","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib126","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1021\/jm0497949","article-title":"Discovery of 1-(3\u2032-aminobenzisoxazol-5\u2032-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2\u2032-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor","volume":"48","author":"Quan","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib127","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/jm020384z","article-title":"Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand","volume":"46","author":"Choi-Sledeski","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib128","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/ATVBAHA.107.139402","article-title":"Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases","volume":"27","author":"Turpie","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2016.05.039_bib129","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.bmcl.2014.12.039","article-title":"Design, synthesis and evaluation of isoxazolo[5,4-d]pyrimidin-4(5H)-one derivatives as antithrombotic agents","volume":"25","author":"Yang","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib130","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1021\/jm200868m","article-title":"Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor","volume":"54","author":"Hirayama","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib131","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1016\/j.bmc.2014.09.059","article-title":"Novel strategy to boost oral anticoagulant activity of blood coagulation enzyme inhibitors based on biotransformation into hydrophilic conjugates","volume":"22","author":"Ishihara","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib132","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.bmc.2014.11.042","article-title":"Identification of potent orally active factor Xa inhibitors based on conjugation strategy and application of predictable fragment recommender system","volume":"23","author":"Ishihara","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib133","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejmech.2015.06.012","article-title":"Synthesis of 3,4-diaminobenzoyl derivatives as factor Xa inhibitors","volume":"101","author":"Yang","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib134","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejmech.2012.10.005","article-title":"Synthesis and structure-activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: application of weakly basic sulfoximine group as novel S4 binding element","volume":"58","author":"Pandya","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib135","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ejmech.2015.03.052","article-title":"Identification of anthranilamide derivatives as potential factor Xa inhibitors: drug design, synthesis and biological evaluation","volume":"95","author":"Xing","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib136","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1016\/j.bmcl.2011.10.021","article-title":"Orally active zwitterionic factor Xa inhibitors with long duration of action","volume":"21","author":"Mochizuki","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib137","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.bmcl.2014.05.101","article-title":"Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties","volume":"24","author":"Orwat","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.039_bib138","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bioorg.2013.11.002","article-title":"New series of 6-substituted coumarin derivatives as effective factor Xa inhibitors: synthesis, in\u00a0vivo antithrombotic evaluation and molecular docking","volume":"52","author":"Amin","year":"2014","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2016.05.039_bib139","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ejmech.2012.06.032","article-title":"Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold","volume":"54","author":"Al-Horani","year":"2012","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523416304378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523416304378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T06:22:03Z","timestamp":1656570123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523416304378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":139,"alternative-id":["S0223523416304378"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2016.05.039","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary developments in the discovery of selective factor Xa inhibitors: A review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2016.05.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}